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Background: A reciprocal relationship between activated innate immune system and changes 
in mood and behavior has been established. There is still a paucity of knowledge on how the 
immune system responds during psychiatric treatment. We aimed to explore circulating cytok-
ines and assess psychiatric symptom severity scores during 12 weeks of inpatient psychiatric 
treatment.
Methods: The study was a longitudinal assessment of 124 patients (88 women and 36 men) 
in treatment at Modum Psychiatric Center, Norway. The patient sample comprised a mixed 
psychiatric population of whom 39 were diagnosed with posttraumatic stress disorder (PTSD). 
Serum blood samples for cytokine analysis and measures of mental distress using Global 
Severity Index were collected at admission (T
0
), halfway (T
1
), and before discharge (T
2
). Other 
factors assessed were age, gender, and the use of antidepressants and anti-inflammatory drugs. 
Multilevel modeling was used for longitudinal analyses to assess the repeated cytokine samples 
within each patient.
Results: Overall level of IL-1RA was higher in PTSD patients when compared to those without 
PTSD (P=0.021). The level of IL-1β, MCP-1, and TNF-α increased over time in PTSD compared 
to non-PTSD patients (P=0.025, P=0.011 and P=0.008, respectively). All patients experienced 
reduced mental distress as measured by self-reported Global Severity Index scores. Stratified 
analysis showed that PTSD patients who used anti-inflammatory drugs had higher levels of 
IL-1β (P=0.007) and TNF-α (P=0.049) than PTSD patients who did not use such drugs.
Conclusion: The study indicates that traumatized patients may have a distinct neuroimmune 
development during recovery. Their activated immune system shows even further activation 
during their rehabilitation despite symptom reduction.
Keywords: cytokines, trauma, inflammation, PTSD, immune activation
Introduction
Patients with various psychiatric disorders have been found to exhibit a low-grade 
inflammatory state characterized by elevated levels of pro- and anti-inflammatory 
cytokines.1,2 In particular, major depression disorder (MDD) and inflammation has 
been extensively studied in the recent years. Cytokine levels have been found to be 
elevated in depression3 and to be reduced over time following treatment.4
The large body of evidence on heightened circulating cytokines in MDD patients 
contrasts the conflicting and lesser evidence on immune response in patients with 
PTSD.5 Previous research has shown both altered immune response and no difference 
from healthy controls in cross-sectional assessments.6 Further, some studies have 
reported that recovery from PTSD and MDD is accompanied by reduction in levels 
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of various pro- and anti-inflammatory cytokines, even to the 
levels of healthy controls, regardless of treatment modality 
or outcome.7,8 Such correlations highlight the possibility that 
specific immune markers may be useful in monitoring and 
intervening in the involved neuroimmune dysregulation.9 
Treatment of patients with PTSD could improve not only 
symptoms but also rebalance the chronic inflammatory 
state, as measured by levels of circulating inflammatory 
cytokines.
Inconsistent findings in previous research could be due to 
various confounders like the use of anti-inflammatory drugs,10 
which might alter inflammatory activity by inhibiting pro-
duction of enzymes COX-1 and COX-2.11 Such drugs have 
been reported to relieve depression symptoms by reducing 
levels of IL-6,12 and also attenuate effects of the antidepres-
sive selective serotonin reuptake inhibitors drugs when used 
in combination.13
We have earlier found bivariate associations between 
trauma and IL-1RA and TNF-α in a cross-sectional 
assessment,14 and we decided to explore these relationships 
longitudinally. Research suggests that the immunological 
response in PTSD patients differs from the response in 
psychiatric patients without PTSD. On this background, we 
hypothesized that patients with PTSD might have higher 
cytokine levels and possibly increasing trajectories over time, 
and thus exhibit an inflammatory pattern different from other 
patients. The aim was to explore levels and development of 
cytokines in PTSD patients vs patients without PTSD, and 
see this in light of their self-reported levels of mental distress, 
taking the use of anti-inflammatory drugs into account.
Materials and methods
study participants and recruitment 
procedure
The study is part of a larger research project and some 
methods have been presented elsewhere.14 The patients 
were recruited from a high-threshold psychiatric center in 
Norway treating patients with depression, anxiety, and eat-
ing or trauma disorders. Enrolled patients have previously 
tried treatment elsewhere with no or little success, many 
of them for years. They were offered a 12 weeks inpatient 
treatment program where a multidisciplinary staff provided 
psychotherapy treatment and psychoeducation both in groups 
and individually. Psychopharmacological treatment was 
used to some extent, but hospital policy restricted the use 
of such drugs to a minimum. Patients with self-destructive 
behavior, severe substance abuse, or psychotic disorders 
were not treated here, but some patients may have had 
comorbid addiction. Data were collected from March 2015 
until April 2016 by the first author. The patients received 
written and oral information about the study during one of 
their first group sessions. Of the 249 patients approached, 
148 (59%) gave their written consent. One patient chose 
to withdraw her consent. We identified 19 patients to have 
extreme cytokine levels above the 95th percentile, and 
they were excluded due to suspected ongoing infections. 
One additional female patient was excluded from cytokine 
analyses due to failed venipuncture, and lastly 4 patients were 
identified as outliers and excluded after residual diagnostics 
was conducted. The study thus consisted of 88 women (71%, 
mean age 38.98 years, SD 11.31) and 36 men (29%, mean 
age 49.06 years, SD 9.36), giving a total of 124 patients. The 
study was approved by the Norwegian Regional Committee 
for Medical and Health Research Ethics prior to data collec-
tion (reference number 2014/2189).
Methods
A psychiatrist or psychologist at the facility performed the 
MINI clinical interview,15 giving diagnosis according to the 
10th Revision of the International Classification of Diseases and 
Related Health Problems (ICD-10). Thirty-one patients met the 
criteria for PTSD diagnosis as their primary disorder, with an 
additional 8 with PTSD as secondary diagnosis, 31 patients with 
mood disorders, 54 with anxiety disorders, and 20 with eating 
disorders. There were 53 patients diagnosed with 1 disorder, 
56 with 2 disorders or more, and 15 patients with no registered 
disorder due to missing data. These 15 patients were excluded 
from analyses involving diagnoses. The symptom severity 
was assessed by the patients themselves using the Hopkins 
Symptom Checklist (HSCL-90R) questionnaire. The patients 
filled out the digital questionnaire on a computer or tablet 3 
times during their stay during one of the first days (T
0
), the 
second at halfway (T
1
), and the last just before discharge (T
2
). 
The 90 questions measure the level of general distress for the 
last 7 days. The answers to each question range from 0 to 4 
and corresponds to “not at all,” “a little bit,” “moderately,” 
“quite a bit,” and “extremely.” Mean score is calculated for 
the HSCL-90R, referred to as the Global Severity Index Index 
(GSI).16 The HSCL-90R has been found to provide valid 
evaluation of the severity of symptoms in a broad range of 
psychiatric patients.17 Based on previous literature, we set the 
cutoff score for caseness at 0.85.18 The drugs that the patients 
used during the stay were recorded by the first author by look-
ing into their medical charts.
Blood collection and serum preparation
The blood samples were also drawn at T
0
, T
1
 and T
2
. The 
blood samples were collected between 08.00 am and 
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09.00 am, except for one of the groups from the department 
of depression, who had their blood drawn between 12.00 am 
and 3.00 pm. Vacuette 8 mL serum containers were used 
for blood collection. These were turned upside-down for 
approximately 8–10 times immediately after the blood was 
drawn, and set to rest in a blood tube stand for a minimum 
of 30 minutes and a maximum of 1 hour. They were then 
centrifuged in a Kubota 2420 swing-out centrifuge set at 
10 minutes. The centrifugation power reached 1,917 g, and 
the centrifugal process was conducted at room temperature. 
Finally, the blood was drawn with 1 mL single-use pipettes 
into Nunc tubes before they were set to rest in -80°C 
until assay.
cytokine and chemokine measurements
We analyzed 7 cytokines and 1 chemokine based on the 
available literature on the neuroimmune correlates of psy-
chiatric disorders. The cytokines were IL-1β, IL-1RA, IL-6, 
IL-10, IL-17A, IFN-y, and TNF-α and the chemokine was 
MCP-1. Four cytokines had too many values under the limit 
of detection (LOD) (55%) and were excluded from the 
study. The following markers were taken into consideration: 
IL-1β, IL-IRA, MCP-1 and TNF-α. All blood samples were 
thawed on ice, vortexed, and then spun down a tube with 
250 µL serum at 14,000× g for 10 minutes at 4°C, before 
before a 4 fold dilution and further processing. Cytokine 
measurements were performed using Bio-Plex xMAP 
technology (Bio-Rad, Austin, TX, USA) with a Luminex 
IS 100 instrument (Bio-Rad), powered using Bio-Plex 
Manager (version 6.0.1) software (Bio-Rad). The assay 
was performed according to the manufacturer’s instruc-
tions, but an additional standard point was included. To 
achieve more reliable results, individual sets of samples 
from patients were run in the same assay, all samples were 
assayed in duplicate and a magnetic plate washer was used 
during assay set up. The StatLIA software package (ver. 
3.2, Brendan Scientific, Carlsbad, CA, USA), incorporat-
ing a weighted, 5-parameter logistic curve-fitting method, 
was used to calculate sample cytokine concentrations. 
Longitudinal controls were used in order to validate interas-
say variation; IL-1β (18.1), IL-1RA (10.2), MCP-1 (6.7), 
and TNF-α (7.4). The interassay percent coefficient of 
variability (CV) in parentheses is a measure of variation 
between plates, where a lower figure is better. Any figure 
below 21% is considered acceptable. The mean interassay 
percent CV for all blood sample plates was 10.4%. The unit 
of measurement was picograms per milliliter (pg/mL). The 
LODs were 0.01 pg/mL for IL-1β, 3 pg/mL for IL-1RA, 
0.76 pg/mL for MCP-1, and 0.02 pg/mL for TNF-α.
imputation
Cytokine levels below LOD were imputed with 1% of the 
mean value. At T
0
 we performed 64 (50.39%) imputations 
for IL-1β, 1 (0.8%) for IL-1RA, 9 (7.1%) for MCP-1, and 53 
(41.7%) for TNF-α. One patient did not have the first blood 
sample collected. At T
1
, there were 62 imputations (51.2%) 
for IL-1β, no imputations for IL-1RA, 5 (5.2%) for MCP-1, 
and 7 (5.8%) for TNF-α. Seven patients did not show up for 
blood sampling at T
1
. At T
2
, we had 64 imputations (53.8%) 
for IL-1β, no imputations for IL-1RA, 8 (7.2%) for MCP-1, 
and 45 (37.8%) for TNF-α. Eleven patients did not show up 
for blood sampling at T
2
.
statistical analyses
The Mann–Whitney U Test, the Wilcoxon signed rank test 
and the Kruskal–Wallis equality-of-populations rank test 
were used for bivariate analyses at T
0
 and to assess differences 
in GSI scores between groups at T
0
, T
1
, and T
2
. Multilevel 
modeling was conducted for longitudinal data analyses.19 
The material comprised 3 observations of each patient, 
which gave a 2-level structure with cytokine measurements 
nested within patients across time. Due to the dependency 
of cytokine measurements within patients, multilevel model-
ing was chosen as the statistical method for the longitudinal 
results. In multilevel modeling, all available data is used. 
Thus, a patient lacking data from one measurement is still 
included and contributes to estimation of model parameters. 
We used a stepwise modeling approach, where the multi-
level models were initially run as empty models including 
only the dependent variable and random intercept. Next, a 
random slope was added in models. The -2 Log Likelihood 
and Bayes Information Criterion (BIC) were performed to 
assess model fit. A model with random intercept and slope 
gave a better fit for all cytokines than a model with random 
intercept only. Patients differed at cytokine levels at treat-
ment initiation, and allowing the patients to have different 
slopes of cytokines during treatment improved model fit. The 
following likelihood ratio tests were performed: IL-1β: χ2(2) 
=17.96, P0.001, IL-1RA: χ2(2) =15.09, P0.001, MCP-1: 
χ2(2) =12.90, P0.001, and TNF-α: χ2(2) =55.85, P0.001. 
The fixed and random effects are presented in Table S1. The 
assumption of homoscedastic residual variance and normally 
distributed residuals was inspected by plotting residual dis-
tribution in histograms and QQ-plots with Gauss curves. It 
was formally confirmed with likelihood ratio tests that the 
residual variance differed over time for IL-1β (χ2[2] =14.01, 
P0.001), for TNF-α (χ2[2] =7.20, P=0.027), and for IL-1RA 
(χ2[2] =55.02, P0.001). Chemokine MCP-1 did not improve 
model fit when we allowed for heteroscedastic residuals 
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(χ2[2] =3.27, P=0.195), and thus the assumption of homo-
scedastic residuals was considered met for MCP-1. Conse-
quently, we allowed for heteroscedastic residual distribution 
for IL-1β, IL-1RA, and TNF-α, which gave a block diagonal 
structure in the covariance matrix for the residuals, allowing 
the estimates in each block to differ. For all four markers, we 
applied robust standard errors to account for nonnormally dis-
tributed errors. The assumption of linearity was confirmed by 
visually inspecting spaghetti plots of cytokine development. 
Unstructured covariance was chosen due to the low number 
of repeated measurements. All multilevel models were in 
addition adjusted for age and gender, which did not signifi-
cantly alter the P-values. Consequently, we chose to present 
the results without this adjustment. Some patient groups had 
different lengths of inpatient stay due to holiday seasons 
and due to minor differences between departments. Because 
of this inequality, the average length of stay for all patient 
groups was calculated. This gave a time variable encoded as 
0 (T
0
), 5 weeks (T
1
), and 11 weeks (T
2
) of stay. For bivariate 
analyses, we attempted to normalize the skewed cytokine data 
by log transformation. The Kolmogorov–Smirnov test of nor-
mality remained significant after log transformation. We also 
explored bivariate analyses with and without log transformed 
data and found no significant changes. We then decided to 
run all analyses with nontransformed data. Those who did 
not attend every blood sample collection were defined as 
missing completely at random (MCAR), which indicated 
no specific pattern of missing data. Consequently, there was 
no increased variability which could bias the regression 
coefficients. MCAR was confirmed by Little’s MCAR test20 
with χ2=9.73 (P=0.973). All tests were 2-sided, and P-values 
below 0.05 were considered statistically significant. No cor-
rection for multiple hypothesis testing was implemented as 
we considered the study to be exploratory. The statistical 
package STATA (StataCorp. 2015, Stata Statistical Software: 
Release 15, StataCorp LP, College Station, TX, USA) was 
used for all statistical analyses.
Results
Table 1 shows the mean cytokine levels across demographic 
variables and sample characteristics at T
0
. Male patients had 
higher levels of chemokine MCP-1 (P=0.046). Patients who 
used anti-inflammatory drugs were found to have higher 
levels of cytokine IL-1β (P=0.038), and almost reached 
significance in levels of TNF-α (P=0.062). Having PTSD 
diagnosis was almost related to higher levels of cytokine 
IL-1RA (P=0.074).
When analyzing the main effect of PTSD and the effect 
of PTSD in interaction with time on cytokines (Table 2), we 
found that the overall level of IL-1RA was higher in PTSD 
than in non-PTSD patients (P=0.021). Patients with PTSD 
showed increasing development of IL-1β (P=0.025), MCP-1 
Table 1 The association between sample characteristics and distribution of cytokine levels at T0
Variables n IL-1β,  
mean (SD)
P-valuea IL-1RA,  
mean (SD)
P-value MCP-1,  
mean (SD)
P-value TNF-α,  
mean (SD)
P-value
gender
Female 87 0.121 (0.032) 0.698 33.894 (2.913) 0.728 23.488 (1.900) 0.046 2.287 (0.548) 0.487
Male 36 0.153 (0.052) 37.971 (5.821) 31.735 (3.997) 2.581 (1.254)
age
18–29 25 0.124 (0.045) 0.537 27.822 (4.104) 0.256 28.716 (4.310) 0.599 1.358 (1.358) 0.394
30–49 62 0.151 (0.045) 36.567 (3.757) 23.639 (2.164) 2.331 (0.830)
50–66 36 0.145 (0.042) 37.585 (5.735) 27.844 (3.920) 3.152 (1.071)
gsi
Under 0.85 25 0.091 (0.030) 0.554 34.643 (6.336) 0.945 29.084 (4.673) 0.642 2.062 (0.904) 0.935
above 0.85 98 0.157 (0.033) 35.200 (2.946) 25.090 (1.931) 2.453 (0.627)
Anti-inflammatory drugs
No 104 0.123 (0.026) 0.038 36.425 (3.088) 0.687 25.701 (1.981) 0.732 2.160 (0.557) 0.062
Yes 19 0.255 (0.101) 27.766 (3.083) 27.002 (4.459) 3.541 (1.606)
antidepressants
No 83 0.137 (0.0287) 0.490 33.598 (2.862) 0.602 27.660 (2.356) 0.121 2.840 (0.716) 0.276
Yes 40 0.157 (0.059) 38.179 (5.678) 22.253 (2.570) 1.405 (0.666)
PTsD diagnosis
No 69 0.101 (0.021) 0.524 31.691 (3.046) 0.074 26.065 (2.106) 0.613 2.221 (0.749) 0.492
Yes 39 0.213 (0.069) 41.563 (5.481) 24.847 (3.162) 3.251 (1.007)
Notes: aP-values for dichotomous variables calculated with the Mann–Whitney U test. P-values for age variable calculated with the Kruskal–Wallis equality-of-populations 
rank test. Statistically significant P-value 0.05 shown in bold.
Abbreviations: gsi, global severity index; PTsD, posttraumatic stress disorder.
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(P=0.011), and TNF-α (P=0.008). The initial levels and 
decreasing GSI score in all patients are visualized in Figure 1. 
Bivariate analysis of GSI score differed between PTSD 
and non-PTSD at T
0
 (P=0.007) and T
2
 (P=0.001). Patients 
without PTSD decreased from T
0
 to T
1
 (P=0.017), from T
1
 
to T
2
 (P=0.003), and from T
0
 to T
2
 (P0.001). Patients with 
PTSD decreased from T
0
 to T
1
 (P=0.024) and from T
0
 to T
2
 
(P=0.051). The level and development of cytokines IL-1β, 
IL-1RA, and TNF-α and chemokine MCP-1 are illustrated 
in Figure 2A–D.
Those of the general patient sample who used anti-
inflammatory drugs during treatment (n=27) were found 
to have higher overall levels of IL-1β (P0.05) than 
those who did not (n=97) use such drugs (Table 3). To 
disentangle the relationship between cytokines, PTSD, and 
anti-inflammatory drugs, we stratified PTSD disorder and ran 
the anti-inflammatory drugs variable as a predictor and in 
interaction with time. The patients with PTSD (Table S2) who 
used anti-inflammatory drugs (n=12) had a higher overall 
level of IL-1β (P=0.007) as compared to PTSD patients who 
did not use such drugs (n=28). We also found a higher overall 
level of TNF-α in this strata (P=0.049). The patients without 
PTSD (Table S3) who used anti-inflammatory drugs (n=13) 
had an overall level of MCP-1 which was higher (P=0.025) 
than in those who did not use such drugs (n=56).
Discussion
In this study, having PTSD disorder was related to higher 
overall level of anti-inflammatory cytokine IL-1RA when 
compared to patients without PTSD diagnosis. An increasing 
development of proinflammatory cytokines IL-1β and TNF-α 
and of proinflammatory chemokine MCP-1 was found. The 
increasing development during treatment occurred in parallel 
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Figure 1 Levels and development (95% CI) of GSI stratified on PTSD diagnosis.
Abbreviations: gsi, global severity index; PTsD, posttraumatic stress disorder.
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with a decreasing level of symptom severity, as indicated by 
the self-reported GSI score.
Our findings are in accordance with some, but not all 
previous research. Studies have found PTSD symptoms to 
decrease over time,10 with increasing IL-1β levels,21 but also 
with decreasing IL-1β levels.22 Increasing levels of TNF-α have 
also been found despite decreasing symptom severity.23 The 
patients who received inpatient psychotherapy, as our patients 
did, showed increasing cytokine levels during treatment. Pos-
sibly, PTSD patients in inpatient intensive treatment reexpe-
rience previous trauma through talk therapy or by exposure 
therapy, while nontraumatized individuals may not have such 
an experience in their therapy sessions. Also, patients suffering 
from PTSD are known to have disruption in their hypothalamic-
pituitary-adrenal (HPA) axis vs immune system feedback and 
may have adapted to prolonged cortisol release24 resulting from 
years of chronic stress, inflammation, and cortisol production. 
In the short term, these responses would be desirable in attempts 
to protect the individual, but the chronic inflammatory activa-
tion in PTSD patients ultimately results in an impaired feedback 
regulation due to glucocorticoid resistance.25
Cytokine TNF-α is regarded as a key inflammatory 
cytokine of the immune response,26 but elevated levels of 
proinflammatory cytokines TNF-α and IL-1β have simul-
taneously been found in PTSD patients when compared to 
controls,27 and it has been postulated that a combination of 
several elevated cytokines may be an indicator of PTSD.26 We 
also found chemokine MCP-1 and cytokine IL-1β to increase 
over time in PTSD patients. It may be that increased TNF-α 
level accompanied by elevated IL-1β and MCP-1 could be 
viewed as biomarkers in PTSD. The increasing inflammatory 
response and the declining GSI score over 12 weeks in the 
current study suggests that PTSD patients who experience 
reduced psychiatric symptoms do not reflect their psycho-
logical improvement at the inflammatory level. Psychiatric 
symptoms were reduced, but this effect could possibly have 
been improved to a greater extent if immune rebalancing 
had occurred in parallel through pharmacotherapy targeting 
the immune system.28
Anti-inflammatory agents have been suggested to reduce 
IL-1β and play a role in future treatment of PTSD.10,29 We 
analyzed anti-inflammatory drug use in the patient sample in 
Figure 2 levels and development (95% ci) of il-1β, il-1ra, McP-1, and TNF-α stratified on PTSD diagnosis.
Notes: (A) The initial level and development (95% ci) over time for cytokine il-1β stratified on PTSD diagnosis. (B) The initial level and development (95% ci) over time 
for cytokine IL-1RA stratified on PTSD diagnosis. (C) The initial level and development (95% CI) over time for chemokine MCP-1 stratified on PTSD diagnosis. (D) The initial 
level and development (95% ci) over time for cytokine TNF-α stratified on PTSD diagnosis.
Abbreviation: PTsD, posttraumatic stress disorder.
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PTsD patients show increasing cytokine levels during treatment
general to get an impression of overall levels and development 
of inflammatory markers. We found a higher level of IL-1β 
in those using anti-inflammatory drugs. As many studies sug-
gest that PTSD patients differ in immunological response,30,31 
we stratified the sample according to PTSD diagnosis. The 
overall levels of IL-1β, MCP-1, and TNF-α were higher in 
PTSD patients who used such drugs. In the strata of patients 
without PTSD who used anti-inflammatory drugs, there was a 
significant relationship with level of chemokine MCP-1. This 
could suggest that patients using anti-inflammatory drugs have 
a reduced immunological response, but PTSD patients do not 
seem to benefit from using such drugs. Anti-inflammatory 
drugs have been postulated as a future remedy in PTSD 
treatment in a systematic review,10 and could potentially have 
contributed to declining cytokine slopes over time if the obser-
vation period had been longer than 12 weeks. However, the 
current results do not lend support to this hypothesis. It should 
be noted that patients who used anti-inflammatory drugs at 
any time point during the stay were coded as users regard-
less of frequency of use. Cytokine levels are likely elevated 
in such patients due to infections and not due to the use of 
anti-inflammatory drugs, which makes cytokine levels in 
this group conditional to confounding by indication. In some 
respect, our results challenge the therapeutic use of pharma-
ceuticals with immunomodulating capabilities in treatment of 
PTSD patients, which has been suggested.6,10,29 Nevertheless, 
antidepressive drugs are hypothesized to partly act on mood 
disorders through anti-inflammatory effects,12,32 and have been 
found to have clinical effect on PTSD symptoms.28,33
A limitation to the present study is that the patients were 
not fasting at blood collection time. Meal frequency has been 
found to be associated with increased cytokine production.34 
Further, body mass index was not measured. Both low and 
high amount of body fat has been reported to affect produc-
tion of proinflammatory cytokines.35 Furthermore, we did not 
assess smoking status. Smokers have been found to have a 
higher basal level of cytokines when compared to nonsmok-
ers.36 It is also important to take into consideration that the 
patients in the current study had their maladies for many years, 
many since their childhood, without improving from other 
psychiatric treatment. As such, they could be regarded as a 
treatment-resistant population with mental and biological sta-
tus more trait-like than state-like. This suggests that 12 weeks 
of observation is a rather short amount of time for observing 
significant changes. This limits the conclusions that can be 
drawn. The reader should bear in mind that there is a risk of 
type 2 errors due to small sample size. The strength of this 
study is that we utilized a longitudinal design and analyzed T
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cytokines over time in a mixed psychiatric population with a 
comparison between PTSD and non-PTSD patients.
Conclusion
Patients with PTSD had higher levels of some inflammatory 
markers, and their levels increased during treatment despite 
a decreasing symptom load.
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Table S1 Fixed- and random-effect estimates for cytokines during treatment
Parameter IL-1β IL-1RA MCP-1 TNF-α
β (SE)a β (SE) β (SE) β (SE)
Fixed effects
intercept 0.147 (0.027)b 34.143 (2.462)b 25.971 (1.783)b 2.373 (0.531)b
slope (time) 0.003 (0.003) -0.134 (0.123) -0.104 (0.106) 0.060 (0.031)c
random effects
intercept 0.070 (0.031) 629.551 (200.348)b 354.747 (104.564)b 34.412 (13.905)b
slope (time) 0.001 (0.001) 0.538 (0.899) 0.633 (0.245)c 0.095 (0.048)c
intercept × slope 0.001 (0.001) -3.783 (6.295) -1.833 (2.526) -0.139 (0.322)
Fit index
-2 ll -56 -1,492 -1,400 -930
Bic 160 3,032 2,835 1,907
Notes: aRegression coefficient. bP0.001. cP0.05. Table S1 shows that the whole patient sample at treatment initiation had an overall level (ie, fixed intercept) of cytokine 
il-1β at 0.147 pg/ml, of il-1ra at 37.143 pg/ml, of McP-1 at 25.971 pg/ml, and of TNF-α at 2.781 pg/ml. These levels were different from zero (P0.001). The significant 
random intercept variance of il-1ra, McP-1, and TNF-α shows that the patients differed significantly from each other at treatment initiation (P0.001). The significant 
random slope for McP-1 and TNF-α shows that the development varied between patients over time (P0.05).
Abbreviations: -2 ll, -2 log likelihood; Bic, Bayes information criterion; se, robust standard error.
Supplementary materials
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